
    
      Design

      Open, non-randomized phase I/II study.

      Purpose:

      Phase I part To find MTD and RFTD for the combination of gemcitabine, oxaliplatin and
      capecitabine.

      Dose Escalating Schedule Dose level Dose Gemcitabine 10 mg/m2/min 600-1000 mg/m2 day 1 and 14
      Capecitabine p.o. x 2 daily. 1000-1250 mg/m2 day 1-7 and 14-21 Oxaliplatin 60-80 mg/m2day 1
      and 14 Drugs: G C O Level 1 600 1000 60 Level 2 800 1000 60 Level 3 1000 1000 60 Level 4 1000
      1250 60 Level 5 1000 1250 80 Level 6 1200 1250 80 Start level: Level 1, 3 patients per level

      Phase II part The primary endpoint is the objective response rate The secondary endpoint is
      toxicity, response duration and time to progression.

      Treatment:

      Gemcitabine Gemcitabine is given intravenously on day 1 and 14 with a fixed dose rate of 10
      mg/m2/min.

      Oxaliplatin Oxaliplatin is given intravenously on day 1 and 14 as a 2 hours infusion.

      Capecitabine Capecitabine is given orally and administered in tablets of 150 mg and 500 mg.
      The dose is administered twice daily with 12 hours interval, in the morning and evening
      during or latest 30 minutes after a meal.
    
  